Here is a chronological list of recent news about AXSM:
- September 14, 2024: Director Mark E. Saad sold 11,016 shares of Axsome Therapeutics at an average price of $91.31, totaling $1,005,870.96. Following the sale, the director owns 10,002 shares1.
- September 11, 2024: Axsome Therapeutics was given a consensus recommendation of "Buy" from the 14 brokerages covering the firm, with an average 12-month price objective of $124.572.
- September 6, 2024: Cantor Fitzgerald reaffirmed an "overweight" rating on AXSM with a price target of $107.003.
- August 6, 2024: UBS Group reduced their price target from $107.00 to $105.00 and maintained a "buy" rating3.
- June 12, 2024: Mizuho reiterated a "buy" rating and set a price target of $106.004.
- September 3, 2024: Wells Fargo & Company initiated coverage on AXSM with an "overweight" rating and a price target of $140.004.
- September 5, 2024: HC Wainwright restated a "buy" rating and issued a price target of $180.004.
- August 14, 2024: StockNews.com downgraded AXSM from a "hold" to a "sell" rating4.
- July 22, 2024: Axsome Therapeutics reported a quarterly earnings per share (EPS) of ($1.24), surpassing the consensus estimate of ($1.30) by $0.061.
- September 16, 2024: Sofinnova Investments Inc. purchased shares of Axsome Therapeutics during the second quarter, buying 310,198 shares valued at approximately $24,971,0005.
This chronological list covers the most recent news about AXSM, including investments, broker ratings and price targets, a director sale, and the company's financial performance.
9/21/2024 05:41pm
